The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
试验速览
- 阶段
- 不适用
- 入组人数
- 880
- 试验地点
- 1
- 主要终点
- Cost in euros per year of healthcare resources related to the management of metastatic NETs patients.
研究概览
简要总结
Neuroendocrine tumours (NETs) are rare and include a heterogeneous group of neoplasms derived from the endocrine system found in the gastrointestinal tract, pancreas and lung. Gastroenteropancreatic (GEP) NETs represent the majority of neuroendocrine neoplasms (NEN) and the annual incidence of all GEP-NETs has been estimated to 6.98 per 100,000 person-years in 2012 and is steadily rising. While data on the incidence of metastatic GEP-NET is limited, more than 50% of patients with GEP-NET have metastatic disease at the time of diagnosis. Incorrect and delayed diagnoses are still common. Treatment options include surgery, locoregional interventions, and systemic treatment.
The Lyon Real world Evidence in Metastatic NeuroEndocrine Tumours study (LyREMeNET) is a descriptive observational cohort study. The main objective is to assess the healthcare resources use and the corresponding costs for management of patients with metastatic GEP and lung NETs. The secondary objective is to describe the clinical characteristics, prognostic factors, treatment patterns, and the overall survival among patients with metastatic GEP and lung NETs.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 15 Years 至 100 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of well-differentiated metastatic neuroendocrine tumour (either synchronous or metachronous)
- •Diagnosis performed between 1 January 1990 and 31 December of 2017
- •Patients seen at least once at the oncologic department of Hospices Civils de Lyon.
排除标准
- •Poorly differentiated neuroendocrine carcinoma
- •Histologic mixed neuroendocrine tumour
结局指标
主要结局
Cost in euros per year of healthcare resources related to the management of metastatic NETs patients.
时间窗: The cost will be calculated, per year, from the date of metastatic diagnosis of NETs to the date of death or last follow-up (study end in September 2018)
次要结局
- Overall survival(From the date of metastatic diagnosis of NETs to the date of death or last-follow-up, through study completion, estimated on september 2018)
- Treatments patterns in metastatic NETs patients(From diagnosis until first occurrence of each treatment, through study completion, estimated on september 2018)